Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

Abstract excerpt

Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to PARP inhibition in cancer therapy
• Share to Plant Virus Research Studies